CN1457783A - Sparxacin dripping pill for resisting bacterial infection and its preparing method - Google Patents
Sparxacin dripping pill for resisting bacterial infection and its preparing method Download PDFInfo
- Publication number
- CN1457783A CN1457783A CN 03136150 CN03136150A CN1457783A CN 1457783 A CN1457783 A CN 1457783A CN 03136150 CN03136150 CN 03136150 CN 03136150 A CN03136150 A CN 03136150A CN 1457783 A CN1457783 A CN 1457783A
- Authority
- CN
- China
- Prior art keywords
- sparfloxacin
- mic
- preparation
- sparxacin
- drop pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is Sparxacin dripping pill and its preparation process. Sparxacin as the antibacterial medicine is added into melt matrix, and the mixture is prepared into Sparxacin dripping pill via cooling in cooler and drying. The Sparxacin dripping pill has the bitter of Sparxacin masked, and has high medicine stability, high digesting rate and high biological utilization as well as quick and lasting antibacterial effect.
Description
Technical field
The present invention relates to preparation of a kind of antibacterials and preparation method thereof, specifically Sparfloxacin drop pill prescription and preparation method thereof.
Technical background
Sparfloxacin (Sparfloxacin) is the fluoroquinolone antibacterial agent that the big Japanese pharmaceutical Co. Ltd of Japan develops, it is to introduce amino on 5 of parent nucleus oxidation chinoline backbone, this medicine is strengthened than the antibacterial activity of other fluoroquinolone antibacterial agents to gram positive bacteria, go up fluoridize for 6 and 8, have 3 on 7,5-lupetazin base makes this medicine weaken interaction with fenbufen, theophylline, probenecid.Change through said structure, its bioavailability is improved, half-life prolongs, strengthened antibacterial activity, streptococcus pneumoniae, mycoplasma, chlamydia, legionella pneumophilia, tubercule bacillus and non-type acid-fast bacilli etc. a little less than the existing fluoroquinolone antimicrobial drug effect have also been shown very strong antibacterial efficacy gram positive bacteria and negative bacterium.The oral metenteron of this product absorbs good, and tissue distribution is wide, and the cell intrinsic permeability is strong, eliminates long half time.Only need take medicine once, and just can bring into play the effect of the various bacterial infections of effective treatment in one day.
1. pharmacological experiments shows: Sparfloxacin is a broad spectrum antibiotic, and gram-positive bacteria is comprised that staphylococcus aureus, staphylococcus epidermidis, micrococcus scarlatinae, streptococcus pneumoniae, enterococcus faecalis have obvious antibacterial action; Gram-negative bacteria escherichia coli, Klebsiella, Salmonella, Shigella, vibrio parahaemolytious, Proteus, Enterobacter, Rhodopseudomonas, acinetobacter, neisseria (Diplococcus gonorrhoeae etc.) also had the excellent antibiotic effect.This product also comprises that to mycoplasma, chlamydia, legionella, anaerobe bacteroides fragilis and Mycobacterium also have the excellent antibiotic effect.
The mechanism of action of Sparfloxacin is to play bactericidal action by the effect that suppresses the DNA gyrase in the DNA of bacteria building-up process.
2. antibacterial activity research
2.1 the antibacterial activity in vitro Sparfloxacin has a broad spectrum antibiotic activity external.It relatively sees table 1 for details with similar medicine.
2.2.1 gram positive bacteria Sparfloxacin most important character is the antibacterial activity enhancing to gram positive bacteria.It is to the MIC of PSSA, MSSA
90SBe respectively 0.125～0.25 and 0.06～0.125mg/L, antibacterial activity is ciprofloxacin, ofloxacin 8～16 times, 2～8 times of levofloxacins, and 32～128 times of norfloxacin slightly are inferior to trovafloxacin; MIC to MRSA
90SBe 8～16mg/L, similar to levofloxacin, its antibacterial activity is ciprofloxacin, ofloxacin 2～4 times, and 4～8 times of norfloxacin are slightly poorer than trovafloxacin.MIC to micrococcus scarlatinae
90SBe 0.25～0.5mg/L, its antibacterial activity and trovafloxacin are close, slightly are better than levofloxacin, are 2～8 times of ciprofloxacin, ofloxacin and norfloxacin 4～16 times.MIC to streptococcus pneumoniae
90SBe 0.125～0.5mg/L, its antibacterial activity is consistent with trovafloxacin, is 4～8 times of levofloxacin, ciprofloxacin, ofloxacin 8～16 times, 64～128 times of norfloxacin.
2.1.2 the gram-negative bacteria Sparfloxacin is to the antibacterial activity and the trovafloxacin basically identical of most gram-negative bacterias, be slightly poorer than ciprofloxacin, slightly be better than levofloxacin, and being better than ofloxacin, norfloxacin, it all shows very strong antibacterial activity to hemophilus influenza and moraxelle catarrhalis, Salmonella, Shigella.
To legionella pneumophilia, the MIC of Sparfloxacin and trovafloxacin
90SBeing 0.015mg/L, is 1/2 of ciprofloxacin, ofloxacin, levofloxacin, norfloxacin; To Aeromonas hydrophila, campylobacter jejuni, the antibacterial activity and the trovafloxacin of Sparfloxacin are approaching, are ciprofloxacin, ofloxacin, levofloxacin 2～8 times, are 8～64 times of norfloxacin.
2.1.3 the anaerobe Sparfloxacin is to the MIC of bacteroides fragilis
90SBe 1～4mg/L, its antibacterial activity is apparently higher than ciprofloxacin, ofloxacin, levofloxacin, and for norfloxacin 64～128 times slightly are inferior to trovafloxacin.Antibacterial activity to the bacillus perfringens Sparfloxacin is better than ciprofloxacin, ofloxacin, levofloxacin and norfloxacin.
2.1.4 mycoplasma, chlamydia and mycobacteria be to mycoplasma pneumoniae, the MIC of Sparfloxacin
90SBe 0.125～0.25mg/L, its sensitivity be better than ciprofloxacin (0.78～2mg/L), the husky star of fluorine oxygen (0.78～2mg/L), but be weaker than erythromycin and clarithromycin (0.06mg/L); To chlamydia trachomatis (MIC
90SBe that 0.03～0.125mg/L) activity is respectively ciprofloxacin, ofloxacin 16～32 times, 2～4 times of erythromycin; MIC to mycobacterium tuberculosis
90SBe 0.5mg/L, obviously be better than ciprofloxacin (1～4mg/L), ofloxacin (0.5～3mg/L), norfloxacin (2～8mg/L).
2.2 the antibacterial activity in vivo Sparfloxacin is to the ED of staphylococcus aureus, micrococcus scarlatinae, streptococcus pneumoniae infection mice
50Be respectively 0.828,3.36 and 6.31mg/kg, its activity in vivo is 5～10 times of ciprofloxacin, 3～7 times of ofloxacin, 12～39 times of enoxacin, 33～56 times of norfloxacin.
Sparfloxacin is to the ED of escherichia coli, charrin disease mice
50Be 0.478 and 1.57mg/kg, its activity in vivo is 1～2 times of ciprofloxacin, 2～4 times of ofloxacin, 5 times of enoxacin, 10～11 times of norfloxacin.The mouse lung that Klebsiella Pneumoniae and Pseudomonas aeruginosa are caused infects its ED
50Be respectively 1.61 and 2.86mg/kg, its activity in vivo is ciprofloxacin, ofloxacin 2～3 times.
To the mice of mycoplasma pneumoniae, chlamydia infection, the activity in vivo of Sparfloxacin is similar to erythromycin, is better than ciprofloxacin, OFLOXACIN ﹠ LEVOFLOXACIN.
2.3 post antibiotic effect post antibiotic effect (PAE) is meant that the antibacterial short burst is exposed to that its growth continues repressed biological effect after the antibacterials.PAE and open-assembly time, antibacterials concentration are proportionate.The PAE that staphylococcus aureus was produced by the 2mg/L effect of Sparfloxacin in 15,30,60 minutes was respectively 52.6 ± 2.0,36.5 ± 4.1,51.0 ± 5.3 minutes.
2.4 empty the dashing forward of drug resistance DNA gyrase A subunit is that antibacterial is to the drug-fast main mechanism of Sparfloxacin.Antibacterial reduces the permeability of medicine, thus lower accumulate in the born of the same parents concentration be the Sparfloxacin drug resistance and with the reason of other class antimicrobial drug crossing drug resistants.Staphylococcus aureus and various gram-negative bacteria are to the drug-fast spontaneous mutation rate of Sparfloxacin＜10
-9, this be MRSA to other fluoroquinolones drug resistances, still keep reason to the Sparfloxacin sensitivity.But existing report confirms the staphylococcus aureus of anti-Sparfloxacin and exists, and owing to crossing drug resistant, MRSA, the streptococcus pneumoniae of anti-Sparfloxacin also are on the increase.
3. toxicologic study mice, rat are pressed the oral Sparfloxacin of body surface area, and dosage is 3.5～6.2 times of human dosage (400mg), in totally 104 weeks, does not see carcinogenesis.Sparfloxacin is not seen mutagenic action to salmonella strain TA98, TA100, TA1535, TA1537 and large intestine dust bacterial strain WP2, but salmonella strain TA102 is had mutagenic action, can cause escherichia coli dna repairing arrangement; Can cause that Chinese Mus pneumonocyte chromosome is not normal under the cell in vitro poison concentration.The male and female rat is 15.4 times of human dosage (400mg) by the oral Sparfloxacin of body surface area, and its fertility, reproductivity are not had obvious influence.
Table 1. Sparfloxacin and similar medicine to the antibacterial action of clinical common pathogenic bacteria (MICs, mg/L)
| Antibacterial | Antibacterial activity | Sparfloxacin | Ciprofloxacin | Ofloxacin | Levofloxacin | Norfloxacin | Trovafloxacin |
| Responsive staphylococcus aureus (PSSA) MSSA (MSSA) methicillin-resistant staphylococcus aureus (MRSA) methicillin-sensitivity MRSE (MSSE) methicillin resistance MRSE (MRSE) micrococcus scarlatinae of gram positive bacteria penicillin streptococcus pneumonia enterococcus faecalis G-group streptococcus Listeria monocytogenes gram-negative bacteria Klebsiella Proteus EHEC enterobacter cloacae clostridium perfringen enterobacter agglomerans takes labor ground other pseudomonad legionella pneumophilia Aeromonas hydrophila campylobacter jejuni NEISSERIA GONORRHOEAE Neisseria meningitidis anaerobic bacteria bacteroides fragilis Bacillus perfringens Bacillus cereus clostridium of citrobacter serratia marcesens acinetobacter calcoaceticus Salmonella Shigella haemophilus influenzae moraxelle catarrhalis pseudomonas aeruginosa | ?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S?MIC 50S?MIC 90S | ?0.06 ?0.125～0.25 ?0.03～0.06 ?0.06～0.125 ?1～8 ?8～16 ?0.125 ?4 ?4～8 ?8～16 ?0.25 ?0.25～0.5 ?0.125～0.25 ?0.125～0.5 ?0.25～0.5 ?0.25～32 ?0.125～0.25 ?0.125～0.5 ?0.125～0.25 ?0.125～0.5 ?0.015～0.06 ?0.06～1 ?0.125～0.25 ?0.25～0.5 ?0.015～0.06 ?0.25～32 ?0.008～0.03 ?0.03～8 ?0.03 ?0.06～2 ?0.06 ?0.125 ?0.06 ?0.25 ?0.125～0.25 ?0.5～4 ?0.008～0.06 ?0.03～16 ?0.03～0.06 ?0.03～0.5 ?0.015 ?0.015～0.03 ?0.004～0.015 ?0.004～0.03 ?0.015～0.06 ?0.03～0.25 ?1～8 ?2～32 ?0.125～1 ?0.5～16 ?0.015 ?0.015 ?0.06 ?0.5 ?0.06 ?0.125 ?0.001 ?0.001 ?0.001～0.004 ?0.001～0.016 ?1 ?1～4 ?≤0.06～0.25 ?- ?0.06 ?0.12 ?- ?0.5～8 | ?0.25～0.5 ?1～2 ?0.25～0.5 ?0.5～2 ?8 ?32～64 ?0.5 ?32 ?8 ?32～64 ?0.25～1 ?0.5～4 ?0.5～4 ?1～4 ?0.5～2 ?1～64 ?0.5～4 ?1～4 ?0.5～4 ?1～4 ?0.015～0.06 ?0.03～2 ?0.03～0.06 ?0.03～0.06 ?0.015～0.03 ?0?25～32 ?0.015～0.03 ?0.06～8 ?0.015 ?0.06～8 ?0.015 ?0.03 ?0.03 ?0.06 ?0.06 ?0.125～4 ?0.06～0.5 ?0.25～256 ?0.015～0.03 ?0.03～0.25 ?0.008～0.015 ?0.008～0.03 ?0.008～0.03 ?0.008～0.03 ?0.06 ?0.06～2 ?0.25～2 ?1～16 ?0.06～0.5 ?0.5～8 ?0.015 ?0.03 ?0.125 ?1 ?0.25 ?1 ?0.001 ?0.001 ?0.004～0.016 ?0.004～0.03 ?2～8 ?4～64 ?0.25～2 ?- ?0.12 ?0.25 ?- ?4～32 | ?0.25～1 ?1～2 ?0.125～0.5 ?0.5～1 ?4～16 ?16～32 ?0.5 ?16 ?8 ?32～64 ?1～2 ?1～8 ?1～4 ?1～8 ?2 ?2～64 ?1～4 ?1～8 ?1～4 ?1～8 ?0.06～0.125 ?0.25～4 ?0.015～0.06 ?0.125～0.25 ?0.06～0.125 ?0.5～32 ?0.015～0.125 ?0.06～1 ?0.125 ?0.25～8 ?0.125 ?0.5 ?0.25 ?1 ?0.25 ?0.5～8 ?0.125～0.5 ?0.5～32 ?0.03～0.125 ?0.03～0.25 ?0.03 ?0.03 ?0.03～0.06 ?0.03 ?0.125～0.25 ?0.125～2 ?2～4 ?4～32 ?0.5～2 ?2～32 ?0.03 ?0.03 ?0.25 ?2 ?0.25 ?0.5 ?0.015 ?0.03～0.08 ?0.06 ?0.06 ?4 ?3.13～50 ?1～2 ?- ?0.12 ?0.25 ?- ?4～16 | ?0.25 ?0.25～1 ?0.06～0.25 ?0.25～0.5 ?2～4 ?8～16 ?0.25 ?4 ?4 ?16 ?0.5 ?0.5～2 ?0.5～1 ?1～2 ?1 ?1～64 ?0.5～1 ?1～2 ?0.5～1 ?1～2 ?0.03～0.006 ?0.125～2 ?0.015～0.06 ?0.06～0.125 ?0.03 ?0?25～16 ?0.008～0.03 ?0.06～8 ?0.03 ?0.06～4 ?0.06 ?0.125 ?0.125 ?0.25 ?0.06～0.125 ?0.125～4 ?0.06～0.5 ?0.25～32 ?0.015～0.06 ?0.03～0.125 ?0.015 ?0.03 ?0.015 ?0.03 ?0.06 ?0.125～1 ?0.5～1 ?2～32 ?0.125～1 ?1～16 ?0.015 ?0.03 ?0.125 ?1 ?0.25 ?0.25 ?- ?- ?0.008 ?0.008 ?2 ?2～12.5 ?0.125～1 ?- ?0.12 ?2 ?- ?2 | ?0.5～2 ?4～16 ?0.5～2 ?2～16 ?32～64 ?32～128 ?1 ?32 ?32～64 ?32～128 ?2～4 ?8～16 ?8～32 ?16～32 ?4 ?32～64 ?8～32 ?16～32 ?8～32 ?16～32 ?0.06～0.125 ?0.125～8 ?0.06～0.125 ?0.125～0.25 ?0.06～0.125 ?0.25～32 ?0.125 ?4～32 ?0.06 ?0.25～32 ?0.125 ?0.25 ?0.125 ?0.5 ?0.125 ?0.25～8 ?0.5～2 ?8 ?0.03～0.25 ?0.03～0.5 ?0.015 ?0.03 ?0.015 ?0.03 ?0.25 ?0.25 ?1～2 ?16 ?1～4 ?4～32 ?0.03 ?0.03 ?0.06 ?4 ?2 ?8 ?0.015 ?0.06～0.1 ?0.06 ?0.125 ?32 ?128～＞256 ?2～8 ?- ?0.5 ?2 ?- ?- | ?0.008～0.06 ?0.06～0.125 ?0.008～0.03 ?0.5～2 ?0.25～4 ?1～16 ?0.06 ?4 ?1～8 ?4～64 ?0.06～0.125 ?0.06～1 ?0.06～0.25 ?0.125～0.5 ?0.25～1 ?0.125～16 ?0.06～0.25 ?0.125～0.5 ?0.06～0.25 ?0.125～0.5 ?0.015～0.125 ?0.06～2 ?0.125～0.25 ?0.25～0.5 ?0.015～0.03 ?0.25～0.5 ?0.015～0.03 ?1～8 ?0.03 ?0.06～16 ?0.03 ?0.06 ?0.06 ?0.25 ?0.25 ?0.25～4 ?0.008～0.06 ?0.03～16 ?0.03～0.125 ?0.06～1 ?0.015 ?0.03 ?0.015 ?0.03 ?0.015～0.125 ?0.015～0.5 ?0.5～8 ?2～32 ?0.125～1 ?1～8 ?0.015 ?0.015 ?0.25 ?0.25 ?0.06 ?0.125 ?0.001 ?0?001 ?0.001 ?0.001 ?0.25～1 ?0.25～2 ?- ?- ?0.03 ?0.12 ?- ?- |
Summary of the invention
The objective of the invention is to by making the Sparfloxacin drop pill, cover worn-out its bitterness, improve stability of drug and dissolution rate, improve bioavailability, bring into play quick-acting, long lasting antibacterial action.
For achieving the above object, the present invention adopts following technical scheme: the active component Sparfloxacin is added in the substrate of melting, stir evenly, the dropping preparation method pill is condensed into ball in the coolant, removes coolant, drying, promptly.
Active component Sparfloxacin in the Sparfloxacin drop pill of the present invention, its English Sparfloxacin by name, chemical name is 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-two fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, structural formula is
Molecular formula is C
19H
22F
2N
4O
3, molecular weight: 392.41.
The used substrate of Sparfloxacin drop pill of the present invention includes but not limited to Macrogol 4000, polyethylene glycol 6000, sodium stearate, glycerin gelatine, poloxamer, stearic acid, glyceryl monostearate, hydrogenated vegetable oil, insect wax etc.
The used coolant of Sparfloxacin drop pill of the present invention includes but not limited to acid solution, Different concentrations of alcohol solution of saline solution, the variable concentrations of liquid paraffin, vegetable oil, kerosene, methyl-silicone oil, water, variable concentrations etc.
Below through detecting explanation beneficial effect of the present invention:
One, detects index and method
Dissolution detects sample thief, and according to dissolution method (two appendix XC first methods of Chinese Pharmacopoeia version in 2000), 1000ml is a solvent with acetic acid-sodium-acetate buffer (pH4.5), Revolution Per Minute 100 changes, operation in the time of 45 minutes, is got solution 10ml in accordance with the law, filter, precision is measured subsequent filtrate 3ml, puts in the 50ml measuring bottle, is diluted to scale with the sodium hydroxide solution of 0.1mol/L, shake up, as need testing solution; Other the Sparfloxacin reference substance that is dried to constant weight of learning from else's experience 105 ℃ is an amount of, with the dissolving of 0.1mol/L sodium hydroxide solution and quantitatively dilution make the solution that contains 6 μ g among every 1ml approximately, product solution in contrast.Get above-mentioned two kinds of solution,, measure trap respectively, calculate every stripping quantity, promptly at the wavelength place of 291nm according to spectrophotography (two appendix IV of Chinese Pharmacopoeia version in 2000 A).
Two, Sparfloxacin sheet (commercially available ordinary tablet) dissolution testing result: 82.3%
Three, example 1 sample dissolution testing result: 99.2%.
Four, example 2 sample dissolution testing results: 98.9%.
Five, example 3 sample dissolution testing results: 97.3%.
Six, example 4 sample dissolution testing results: 98.1%.
The specific embodiment
One, example 1
Sparfloxacin 100g
Polyethylene glycol 6000 900
Two, example 2
Sparfloxacin 100g
Sodium stearate 600g
Insect wax 200g
Three, example 3
Sparfloxacin 100g
Macrogol 4000 900g
Four, example 4
Sparfloxacin 100g
Glyceryl monostearate 900g
Above examples preparation method: get the substrate heating and make melting, add Sparfloxacin, stir evenly, splash under the heat-retaining condition and be cooled to ball in the coolant, collect drop pill, drying, promptly.
Claims (4)
1. Sparfloxacin drop pill and preparation method thereof is characterized in that: it is that the active component Sparfloxacin is added in the substrate of melting, stirs evenly, and the dropping preparation method pill removes coolant after being condensed into ball in the coolant, and drying forms.
2. the active component Sparfloxacin in Sparfloxacin drop pill according to claim 1 and preparation method thereof, its English Sparfloxacin by name, chemical name is 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-two fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, structural formula is
Molecular formula is C
19H
22F
2N
4O
3, molecular weight: 392.41.
3. the substrate in Sparfloxacin drop pill according to claim 1 and preparation method thereof includes but not limited to Macrogol 4000, polyethylene glycol 6000, sodium stearate, glycerin gelatine, poloxamer, stearic acid, glyceryl monostearate, hydrogenated vegetable oil, insect wax etc.
4. the coolant in Sparfloxacin drop pill according to claim 1 and preparation method thereof includes but not limited to acid solution, Different concentrations of alcohol solution of saline solution, the variable concentrations of liquid paraffin, vegetable oil, kerosene, methyl-silicone oil, water, variable concentrations etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03136150 CN1457783A (en) | 2003-05-17 | 2003-05-17 | Sparxacin dripping pill for resisting bacterial infection and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03136150 CN1457783A (en) | 2003-05-17 | 2003-05-17 | Sparxacin dripping pill for resisting bacterial infection and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1457783A true CN1457783A (en) | 2003-11-26 |
Family
ID=29430645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03136150 Pending CN1457783A (en) | 2003-05-17 | 2003-05-17 | Sparxacin dripping pill for resisting bacterial infection and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1457783A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008151502A1 (en) * | 2007-06-08 | 2008-12-18 | Hainapharm Pharmaceutical Co., Ltd. Foshan | Enrofloxacin microcapsule formulation and preparation method thereof |
| CN113980889A (en) * | 2021-11-03 | 2022-01-28 | 复旦大学附属中山医院 | Medicinal preparation for resisting intracellular mycoplasma infection and application thereof |
-
2003
- 2003-05-17 CN CN 03136150 patent/CN1457783A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008151502A1 (en) * | 2007-06-08 | 2008-12-18 | Hainapharm Pharmaceutical Co., Ltd. Foshan | Enrofloxacin microcapsule formulation and preparation method thereof |
| CN113980889A (en) * | 2021-11-03 | 2022-01-28 | 复旦大学附属中山医院 | Medicinal preparation for resisting intracellular mycoplasma infection and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoban et al. | Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999 | |
| Zhong et al. | Antibiotic susceptibility of Riemerella anatipestifer field isolates | |
| Lees | Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat | |
| Gwon | Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. | |
| Wu et al. | Epidemiology, environmental risks, virulence, and resistance determinants of Klebsiella pneumoniae from dairy cows in Hubei, China | |
| CN1457783A (en) | Sparxacin dripping pill for resisting bacterial infection and its preparing method | |
| Yamaguchi et al. | Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002 | |
| CN108379258B (en) | Application of daphnetin in resisting helicobacter pylori | |
| CN107441494B (en) | Chitosan oligosaccharide and antibiotic with antibacterial film activity and application thereof | |
| CN1457782A (en) | Dry spaxxacin suspension agent for resisting bacterial infection and its preparing method | |
| Ohnsman et al. | Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis | |
| CN101690712B (en) | Sitafloxacin eye drop and preparation method thereof | |
| CN107802652B (en) | Application of inactivated lactobacillus in medicine for preventing and treating bacterial diseases | |
| Hammadi | Antimicrobial resistance and presence of Class 1 integrons in Pseudomonas aeruginosa isolates from burn and wound infections | |
| de Lastours et al. | Evolution of fluoroquinolone-resistant Escherichia coli in the gut after ciprofloxacin treatment | |
| CN107375211B (en) | Children sublingual spray of tosufloxacin tosylate and preparation method thereof | |
| Tanaka et al. | Genotypic evolution in a quinolone-resistant Neisseria gonorrhoeae isolate from a patient with clinical failure of levofloxacin treatment | |
| CN101092643B (en) | Culture medium for asepsis test in medication of quinolone category, and application | |
| Bamisaye et al. | Generation, characterization and pharmacokinetic study of ofloxacin-loaded castor oil based nanoemulsion | |
| Meena et al. | Moxifloxacin and its therapeutic uses in animals: An overview | |
| CN1817340A (en) | Composition of sodium fusidafe as injection and preparing method thereof | |
| Deguchi et al. | Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC | |
| Xue et al. | Temporal impacts of topical ceftazidime and tobramycin-vancomycin mixtures on the ocular surface microbiota in rabbits | |
| CN101181271A (en) | Water-soluble salt of aspartic acid carbostyril series antibacterial drugs and injection dosage forms thereof | |
| Assar et al. | Expression of DNA gyrase at mRNA levels and antibacterial effect of fluoroquinolone-derived compounds on two antibiotic resistant bacteria; Staphylococcus aureus and Enterococcus faecalis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |